v3.25.2
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 3 Months Ended
Jun. 28, 2025
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
17. SEGMENT AND ENTERPRISE-WIDE INFORMATION
The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Company’s Chief Executive Officer.
The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital
The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of the Company’s enterprise resource planning system, impairments and write downs, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration liability and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. During the fourth quarter of fiscal 2025, the CODM began reviewing financial information including allocations of certain corporate costs including global functional support and overhead costs determined to benefit the segments. The prior period segment disclosures have been recast to reflect the new presentation.
The Company does not track its assets by segment, and as a result it is not practical to show assets or depreciation by segment. Consequently, the Company’s CODM does not review assets by segment when assessing business performance and allocating resources.
Selected information by reportable segment is presented below:
Three Months Ended
June 28, 2025June 29, 2024
(Dollars in Thousands)
Net revenues:
Plasma$129,897 $135,910 
Blood Center51,839 66,245 
Hospital139,658 134,017 
Total net revenues$321,394 $336,172 
Significant segment expenses and operating performance:
Plasma
Cost of goods sold$49,917 $65,338 
Selling, general and administrative26,198 25,130 
Research and development5,497 3,719 
Plasma operating income$48,285 $41,723 
Blood Center
Cost of goods sold$25,948 $36,180 
Selling, general and administrative13,682 15,602 
Research and development1,319 1,684 
Blood Center operating income$10,890 $12,779 
Hospital
Cost of goods sold$50,216 $48,685 
Selling, general and administrative62,323 61,190 
Research and development8,742 7,623 
Hospital operating income$18,377 $16,519 
Corporate and unallocated expenses
Amortization of acquired intangible assets$(13,828)$(17,710)
Acquisition, integration and divestiture related costs(2,682)(12,323)
Restructuring and restructuring related costs(1,324)(7,140)
Digital transformation costs(5,355)(6,345)
Remeasurement of contingent consideration93 — 
Other(1)
(584)12,253 
Operating income53,872 39,756 
Interest and other (expense) income, net(8,703)6,957 
Income before provision for income taxes$45,169 $46,713 
__________
(1)    Comprised of litigation-related charges for the three months ended June 28, 2025. Comprised of MDR and IVDR costs, litigation-related charges, and gains on sale of property, plant and equipment for the three months ended June 29, 2024.
Net revenues by business unit are as follows:
 Three Months Ended
June 28, 2025June 29, 2024
(Dollars in Thousands)
Plasma
Plasma net revenues$129,897 $135,910 
Blood Center
Apheresis51,822 49,094 
Whole Blood17 17,151 
Blood Center net revenues51,839 66,245 
Hospital
Interventional Technologies58,483 63,044 
Blood Management Technologies81,175 70,973 
Hospital net revenues139,658 134,017 
Total net revenues$321,394 $336,172 
Depreciation and amortization, excluding impairment charges, by business unit are as follows:
Three Months Ended
June 28, 2025June 29, 2024
(Dollars in Thousands)
Plasma$12,153 $11,916 
Blood Center1,759 3,453 
Hospital14,846 13,767 
Total depreciation and amortization (excluding impairment charges)$28,758 $29,136 
Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:
June 28, 2025March 29, 2025
(Dollars in Thousands)
Plasma$193,740 $189,833 
Blood Center38,412 40,337 
Hospital54,713 53,882 
Total long-lived assets$286,865 $284,052 
Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:
June 28, 2025March 29, 2025
(Dollars in Thousands)
United States$213,834 $217,212 
Japan1,228 1,250 
Europe24,177 20,024 
Rest of Asia29,828 28,705 
Other17,798 16,861 
Total long-lived assets$286,865 $284,052 
Net revenues by operating regions are as follows:
Three Months Ended
June 28, 2025June 29, 2024
(Dollars in Thousands)
United States$242,404 $248,902 
Japan13,648 13,705 
Europe40,882 47,225 
Rest of Asia21,648 19,783 
Other2,812 6,557 
Total net revenues$321,394 $336,172